Close Menu

NEW YORK (GenomeWeb) – Amoy Diagnostics said today that the Chinese National Medical Products Administration (NMPA) has approved its BRCA1 and BRCA2 gene mutation detection kit.

The next-generation sequencing-based kit is designed for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including ovarian cancer and breast cancer, and is the first BRCA gene mutation detection product approved in China, AmoyDx said.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.